Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized adjuvant chemotherapy based on chemosensitivity-related molecular profiling after pancreatic cancer surgery
ChiCTR-IIR-17013406Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, oxaliplatin and fluorouracil in pancreatic cancer (PC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free survival. Started Nov 2017; status: recruiting.
02
Drugs
gemcitabineoxaliplatinfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR-IIR-17013406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013406.